Business Context and Reporting Period
Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on dermatology. The reporting period covers the three and nine months ended September 30, 2015. The company's lead drug candidate, A-101, is a topical solution for seborrheic keratosis (SK). As of the filing date, the company had not generated any product revenue and was preparing for its Initial Public Offering (IPO), which closed on October 13, 2015.
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 2015 | 9 Months Ended Sep 30, 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(15.8 million) | $(5.9 million) |
| Net Loss Attributable to Common Stockholders | $(18.2 million) | $(7.3 million) |
| Research & Development Expenses | $12.9 million | $4.5 million |
| General & Administrative Expenses | $2.9 million | $1.5 million |
| Cash and Cash Equivalents (Sep 30, 2015) | $25.4 million | $10.8 million (Dec 31, 2014) |
| Marketable Securities (Sep 30, 2015) | $13.0 million | $5.4 million (Dec 31, 2014) |
| Total Liquidity (Cash + Securities) | $38.4 million | $16.1 million (Dec 31, 2014) |
| Accumulated Deficit | $(38.1 million) | $(20.7 million) (Dec 31, 2014) |
| Convertible Preferred Stock (Carrying Value) | $78.3 million | $36.7 million (Dec 31, 2014) |
Material Changes vs. Prior Period
- Significant Increase in R&D Expenses: R&D expenses rose by $8.5 million (191%) year-over-year. This was primarily driven by an $8.0 million upfront payment to Rigel Pharmaceuticals, Inc. for the exclusive license of JAK inhibitors for dermatological conditions. This payment was expensed immediately as an asset acquisition.
- Increased Operating Loss: Net loss for the nine months ended September 30, 2015, increased to $15.8 million from $5.9 million in the prior year period, largely due to the Rigel license fee and increased operational costs.
- Capital Raise: The company issued Series C convertible preferred stock in August 2015, raising gross proceeds of $40.0 million. This significantly improved liquidity compared to the prior period.
- Stock-Based Compensation: Stock-based compensation expense increased to $0.2 million for the nine months ended September 30, 2015, from $0.01 million in the prior year period.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur significant operating losses for the foreseeable future. The company plans to commence three Phase 3 clinical trials for A-101 in the first quarter of 2016 and submit a New Drug Application (NDA) in the fourth quarter of 2016.
- Liquidity: As of September 30, 2015, the company held $38.4 million in cash and marketable securities. Following the October 2015 IPO, which generated net proceeds of approximately $56.6 million, management believes funds are sufficient to operate for at least the next 24 months.
- Key Risks:
- Development Risk: No products are approved; success depends on clinical trial results and regulatory approval.
- Capital Needs: The company will require substantial additional funding for commercialization and further development.
- Reimbursement: Success for A-101 in treating SK may depend on patients paying out-of-pocket, as third-party payors generally do not cover cosmetic procedures.
- Intellectual Property: Reliance on licensed IP from Rigel and potential patent challenges.
Investor Verification Checklist
- Post-IPO Liquidity: Verify the actual cash balance post-IPO (October 2015) to confirm the 24-month runway estimate.
- Rigel Agreement Terms: Review the specific milestones triggering the remaining $90 million in potential payments to Rigel Pharmaceuticals.
- Phase 3 Trial Initiation: Monitor the commencement of Phase 3 trials for A-101 in Q1 2016 as planned.
- Reimbursement Strategy: Assess the company's strategy for securing third-party payer coverage or managing out-of-pocket patient costs for SK treatment.
- Preferred Stock Conversion: Confirm the full conversion of all Series A, B, and C preferred stock into common stock following the IPO closing.